Physician profile
Pankaj Satija
NPI 1831352616
$1,053,506.46
in general payments reported to CMS, 2019-2025
72 companies · $166K in 2025
The $166K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136K · 2020: $100K · 2021: $186K · 2022: $212K · 2023: $122K · 2024: $130K · 2025: $166K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $339K · Honoraria: $43K · Travel and Lodging: $20K · Food and Beverage: $14K · Consulting Fee: $1,800 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $339,210.00 |
| Honoraria | $43,321.50 |
| Travel and Lodging | $19,724.22 |
| Food and Beverage | $14,412.04 |
| Consulting Fee | $1,800.00 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $552,059.89 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Amgen INC. | $180,379.89 | 2019-2023 | Aimovig |
| Biohaven Pharmaceutical Holding Company Ltd. | $76,164.06 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $52,452.77 | 2021 | |
| Lilly USA, LLC | $50,449.20 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Axsome Therapeutics, INC. | $47,523.73 | 2025 | Symbravo |
| Teva Pharmaceuticals USA, INC. | $38,528.07 | 2019-2024 | Ajovy |
| Allergan, INC. | $25,926.65 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,611.04 | 2019-2025 | Relistor |
| Medtronic, INC. | $3,340.17 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Lundbeck LLC | $2,345.15 | 2020-2025 | Vyepti |
| Pfizer INC. | $2,156.68 | 2019-2025 | |
| Medtronic USA, INC. | $2,151.72 | 2019-2020 | |
| Abbott Laboratories | $1,756.72 | 2019-2023 | Proclaim |
| Daiichi Sankyo INC. | $1,535.00 | 2019 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankaj Satija listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.